Jefferies Group’s TherapeuticsMD TXMD Stock Holding History

Jefferies Group’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,448	Closed	-$444K	–	3022
2019 Q3	$444K	Buy	2,448 +448	+22%	+$63.1K	﹤0.01%	1949
2019 Q2	$260K	Buy	+2,000	New	+$359K	﹤0.01%	1998

Other funds holding TXMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Group's TXMD Position: Q2 2020 in Review

Jefferies Group sold out of TherapeuticsMD (TXMD) in Q2 2020, closing a stake of 1,401 shares — an estimated $74K sold.

Jefferies Group first reported a position in TXMD in Q1 2014 and held it in 12 quarters. The position peaked at $7.66M in Q1 2014. 149 funds tracked by Wall St. Rank hold TXMD as of Q2 2020.

Jefferies Group reported no remaining TherapeuticsMD position as of Q2 2020 after selling out during the quarter.
Jefferies Group sold 1,401 TherapeuticsMD shares in Q2 2020, an estimated $74K.
Jefferies Group first reported a position in TherapeuticsMD in Q1 2014 and held it in 12 quarters.
Jefferies Group's TherapeuticsMD position peaked at $7.66M in Q1 2014.
149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2020.

Based on Jefferies Group's 13F filing for Q2 2020, filed 14 Aug 2020.